Abraxis BioScience, Inc., a fully microcircuit biotechnology company, today announced that the Office of Orphan seconds growth of the Food and Drug direction (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable abeyancy (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the rehabilitation of pancreatic cancer as well as stage IIB-IV melanoma.

More: - Continued here